Compare Stocks: ZYME, PRAX, CYTK, and ABVX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$86.59 -2.8%	$100.14	$69.81 ▼ $148.83	$7.58B	1.14	1.07 million shs	842,498 shs
CYTK Cytokinetics	$62.99 -0.5%	$67.50	$58.05 ▼ $88.31	$7.84B	0.41	1.75 million shs	1.26 million shs
PRAX Praxis Precision Medicines	$285.93 -0.9%	$301.28	$154.45 ▼ $392.70	$7.98B	2.79	534,513 shs	306,411 shs
ZYME Zymeworks	$28.61 -0.3%	$27.30	$16.00 ▼ $31.34	$2.02B	1.17	1.30 million shs	2.88 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	0.00%	-1.61%	-8.95%	-30.68%	-12.48%
CYTK Cytokinetics	0.00%	+2.87%	-4.01%	-18.33%	+1.61%
PRAX Praxis Precision Medicines	0.00%	+13.03%	-0.34%	-7.11%	+46.06%
ZYME Zymeworks	0.00%	+1.38%	+10.21%	+30.40%	+47.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$86.59 -2.8%	$100.14	$69.81 ▼ $148.83	$7.58B	1.14	1.07 million shs	842,498 shs
CYTK Cytokinetics	$62.99 -0.5%	$67.50	$58.05 ▼ $88.31	$7.84B	0.41	1.75 million shs	1.26 million shs
PRAX Praxis Precision Medicines	$285.93 -0.9%	$301.28	$154.45 ▼ $392.70	$7.98B	2.79	534,513 shs	306,411 shs
ZYME Zymeworks	$28.61 -0.3%	$27.30	$16.00 ▼ $31.34	$2.02B	1.17	1.30 million shs	2.88 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	0.00%	-1.61%	-8.95%	-30.68%	-12.48%
CYTK Cytokinetics	0.00%	+2.87%	-4.01%	-18.33%	+1.61%
PRAX Praxis Precision Medicines	0.00%	+13.03%	-0.34%	-7.11%	+46.06%
ZYME Zymeworks	0.00%	+1.38%	+10.21%	+30.40%	+47.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	2.88	Moderate Buy	$155.00	79.00% Upside
CYTK Cytokinetics	2.86	Moderate Buy	$105.44	67.40% Upside
PRAX Praxis Precision Medicines	2.95	Moderate Buy	$630.42	120.48% Upside
ZYME Zymeworks	2.79	Moderate Buy	$41.67	45.64% Upside

Current Analyst Ratings Breakdown

Latest ZYME, PRAX, CYTK, and ABVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/27/2026	ZYME Zymeworks	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$34.00 ➝ $35.00
10/26/2026	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/23/2026	ZYME Zymeworks	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$52.00
10/21/2026	ABVX Abivax	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
10/21/2026	ABVX Abivax	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$118.00 ➝ $96.00
10/20/2026	ABVX Abivax	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$175.00
10/19/2026	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$140.00
10/16/2026	CYTK Cytokinetics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/16/2026	PRAX Praxis Precision Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$700.00
10/15/2026	ABVX Abivax	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	CYTK Cytokinetics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 11/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$6.57 per share	N/A
CYTK Cytokinetics	$88.04M	89.03	N/A	N/A	($5.39) per share	-11.69
PRAX Praxis Precision Medicines	$8.55M	933.70	N/A	N/A	$34.85 per share	8.20
ZYME Zymeworks	$105.96M	19.03	N/A	N/A	$3.59 per share	7.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$380.27M	-$6.06	N/A	N/A	N/A	N/A	-91.69%	-71.96%	12/21/2026 (Estimated)
CYTK Cytokinetics	-$784.96M	-$7.22	N/A	N/A	N/A	-1,321.12%	N/A	-51.01%	11/4/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/9/2026 (Estimated)
ZYME Zymeworks	-$81.13M	-$2.02	N/A	22.53	N/A	-405.31%	-72.30%	-37.18%	11/9/2026 (Estimated)

Latest ZYME, PRAX, CYTK, and ABVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	PRAX Praxis Precision Medicines	-$3.54	N/A	N/A	N/A	$0.13 million	N/A
11/9/2026	Q3 2026	ZYME Zymeworks	$2.27	N/A	N/A	N/A	$227.40 million	N/A
11/4/2026	Q3 2026	CYTK Cytokinetics	-$1.44	N/A	N/A	N/A	$41.88 million	N/A
9/21/2026	Q2 2026	ABVX Abivax	-$0.9170	-$1.71	-$0.7930	-$1.68	$0.80 million	$1.37 million
8/7/2026	Q2 2026	ZYME Zymeworks	-$0.5620	-$0.62	-$0.0580	-$0.62	$4.54 million	$3.23 million
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	-$1.50	+$0.13	-$1.50	$17.59 million	$28.62 million
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	N/A	5.97	5.97
CYTK Cytokinetics	N/A	6.66	6.66
PRAX Praxis Precision Medicines	N/A	15.73	15.73
ZYME Zymeworks	N/A	6.32	6.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
CYTK Cytokinetics	N/A
PRAX Praxis Precision Medicines	67.84%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
CYTK Cytokinetics	2.60%
PRAX Praxis Precision Medicines	3.00%
ZYME Zymeworks	33.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	80	87.55 million	N/A	Optionable
CYTK Cytokinetics	673	124.43 million	121.20 million	Optionable
PRAX Praxis Precision Medicines	168	27.92 million	27.08 million	Optionable
ZYME Zymeworks	264	70.47 million	46.86 million	Optionable

ZYME, PRAX, CYTK, and ABVX Headlines

Recent News About These Companies

Zymeworks (ZYME) Receives a Buy from Truist Financial

October 31 at 7:59 AM | theglobeandmail.com

Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates - Slideshow

October 29 at 7:14 PM | seekingalpha.com

Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth

October 29 at 11:01 AM | zacks.com

Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors

October 27, 2026 | biospace.comB

Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside

October 27, 2026 | marketbeat.com

Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript

October 27, 2026 | seekingalpha.com

Stifel Nicolaus Keeps Their Buy Rating on Zymeworks (ZYME)

October 27, 2026 | theglobeandmail.com

Zymeworks Inc. Submits 10-K Annual Report for Fiscal Year Ending December 31, 2025

October 27, 2026 | kalkinemedia.comK

Another autoimmune CAR-T death; Treasury zeroes in on China deals

October 26, 2026 | biopharmadive.comB

How Investors Are Reacting To Zymeworks (ZYME) Roche Licensing Deal

October 26, 2026 | finance.yahoo.com

Zymeworks Inc. ($ZYME) CEO 2025 Pay Revealed

October 26, 2026 | quiverquant.comQ

Zymeworks (NASDAQ: ZYME) inks Roche deal with up to $718 million in milestones

October 26, 2026 | americanbankingnews.com

Zymeworks Inc. Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate Zw191 At ESMO Congress 2026

October 24, 2026 | marketscreener.comM

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

October 24, 2026 | globenewswire.com

Zymeworks Signs Roche Deal with $55 Million Upfront, Up to $718 Million in Milestones

October 23, 2026 | finance.yahoo.com

Zymeworks signs Roche DLL3 deal, up to $813M

October 23, 2026 | ijr.comI

Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal

October 23, 2026 | msn.com

Roche pays Zymeworks $55M for trispecific challenger to Amgen’s Imdelltra

October 23, 2026 | fiercebiotech.comF

Roche pays $55 million upfront for Zymeworks’ DLL3 T cell engager ZW209

October 23, 2026 | thepharmaletter.comT

Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche

October 23, 2026 | pharmexec.comP

Zymeworks Inc. Enters Into An Exclusive Global License And Collaboration Agreement With F. Hoffmann-La Roche Ltd And Hoffmann-La Roche Inc. For ZW209, A Trispecific T Cell ...

October 23, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME, PRAX, CYTK, and ABVX Company Descriptions

Abivax NASDAQ:ABVX

$86.59 -2.47 (-2.77%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$86.58 -0.01 (-0.02%)

As of 10/30/2026 07:41 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Cytokinetics NASDAQ:CYTK

$62.99 -0.32 (-0.51%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$63.50 +0.51 (+0.81%)

As of 10/30/2026 07:30 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Praxis Precision Medicines NASDAQ:PRAX

$285.93 -2.69 (-0.93%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$286.06 +0.13 (+0.05%)

As of 10/30/2026 07:51 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Zymeworks NASDAQ:ZYME

$28.61 -0.10 (-0.35%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$29.00 +0.39 (+1.36%)

As of 10/30/2026 05:26 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZYME, PRAX, CYTK, and ABVX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZYME, PRAX, CYTK, and ABVX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZYME, PRAX, CYTK, and ABVX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME, PRAX, CYTK, and ABVX Company Descriptions

Abivax NASDAQ:ABVX

Cytokinetics NASDAQ:CYTK

Praxis Precision Medicines NASDAQ:PRAX

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZYME, PRAX, CYTK, and ABVX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZYME, PRAX, CYTK, and ABVX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZYME, PRAX, CYTK, and ABVX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME, PRAX, CYTK, and ABVX Company Descriptions

Abivax NASDAQ:ABVX

Cytokinetics NASDAQ:CYTK

Praxis Precision Medicines NASDAQ:PRAX

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools